Akero Therapeutics, Inc..
AKRO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Akero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH). Their lead product candidate, efruxifermin (EFX), is a novel, injectable fibroblast gro...Show More
Better Health for All
40
Akero Therapeutics is a clinical-stage biopharmaceutical company entirely focused on developing efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH), a severe chronic liver disease affecting millions.
1
In a mid-stage study, EFX significantly reduced liver scarring, with 75% of patients on a higher dose achieving at least one stage of fibrosis improvement without MASH worsening at 96 weeks, compared to 24% for placebo.
2
Over a third (36%) achieved at least two stages of improvement.
3
The company's entire business model is dedicated to addressing this unmet medical need, with 100% of its R&D budget allocated to health improvement. Mild to moderate gastrointestinal adverse events were more common with efruxifermin than placebo, but no drug-induced liver injury or deaths were reported across the groups.
4
The company conducts randomized, double-blind, placebo-controlled clinical trials, registered with ClinicalTrials.gov, with participants, investigators, pathologists, site staff, and the sponsor masked to group assignments.
5
The trials include adults aged 18–75 years with biopsy-confirmed MASH and F2 or F3 fibrosis, with 62% female and 38% male participants.
6
Fair Money & Economic Opportunity
0
Akero Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic diseases.
1
The provided articles discuss clinical trials, financial results, and stock offerings, but contain no information related to financial services, lending, or economic opportunity initiatives for consumers. As the company's core business lies outside the financial sector and it does not offer financial products or services to consumers, all KPIs under the 'Fair Money & Economic Opportunity' value are not applicable and lack specific, concrete data points for evaluation.
Fair Pay & Worker Respect
20
In 2024, Akero Therapeutics, Inc. reported a CEO pay ratio of 22:1, which is the CEO's total compensation divided by the median employee pay.
1
No specific regulatory actions, violations, fines, or compliance issues related to labor laws or human rights are mentioned in the provided articles.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Akero Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Akero Therapeutics, Inc. on Honest & Fair Business.
Kind to Animals
-40
Akero Therapeutics conducts pre-clinical studies on animals to assess drug safety, including 90 or 120-day chronic toxicity animal studies.
1
The company explicitly stated in a report that they exploit animals for product testing, indicating that animal testing is a routine and integral part of their drug development process.
2
No War, No Weapons
0
No evidence available to assess Akero Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
0
The provided articles do not contain any specific quantitative data or concrete facts regarding Akero Therapeutics, Inc.'s performance on any of the Planet-Friendly Business KPIs. The articles mention general ESG rankings and risk scores but explicitly state that specific sustainability metrics are not available or are behind premium access.
1
Therefore, no KPIs can be scored based on the evidence provided.
Respect for Cultures & Communities
0
No data relevant to the 'Respect for Cultures & Communities' value or any of its associated KPIs was found in the provided articles.
1
The articles focus on the company's research and development efforts and clinical trial data, without addressing corporate social responsibility, community engagement, or cultural sensitivity metrics.
2
Safe & Smart Tech
0
The company reports no material cybersecurity incidents and no incidents of unauthorized data use.
1
Its privacy policy mentions user rights to update, correct, delete data, and opt out of sales or sharing, which aligns with industry-standard user privacy controls.
2
The company utilizes third-party security testing firms and conducts external lead assessments, indicating standard vulnerability management and security testing practices.
3
The company states compliance with applicable laws, but no specific regulatory compliance details are given.
4
Zero Waste & Sustainable Products
0
No specific, quantitative data related to waste management, product sustainability, or circular economy metrics for Akero Therapeutics, Inc. was found in the provided articles.
1
The articles primarily discuss the company's general ESG risk rating, which is categorized as 'High' (39.1), and compare it to peer companies based on this overall rating, but do not offer details on any of the specific KPIs for Zero Waste & Sustainable Products.
2